Table 1.
Baseline demographic and clinical characteristics of the study population
| Demographic and clinical data | Overall population | Device group | Control group |
|---|---|---|---|
| Number of patients | 86 | 58 | 28 |
| Age (years) * | 71 ± 10 | 72 ± 10 | 71 ± 11 |
| Male sex, N (%) * | 67 (76.1%) | 42 (72.4%) | 25(86.2%) |
| NYHA class * | 3.1 ± 0.6 | 3.2 ± 0.5 | 3.0 ± 0.5 |
| Dilated cardiomyopathy * (%) | 31 | 32.8 | 29.2 |
| CRT implantation * | 34.9 | 34.5 | 37.5 |
| Atrial fibrillation * (%) | 45 | 49.1 | 37.5 |
| 6MWT * (m) | 255 ± 139 | 240 ± 144 | 288 ± 124 |
| QoL questionnaire * (%) | 44 ± 18 | 43 ± 17 | 47 ± 19 |
| BNP * (median, pg/mL) | 614 | 627 | 454 |
| Logistic EuroSCORE * (%) | 23 ± 17 | 23 ± 15 | 26 ± 21 |
| ACE inhibitors * (%) | 89.2 | 93.1 | 83.3 |
| B blockers * (%) | 96.4 | 96.6 | 100 |
| Diuretics * (%) | 100 | 100 | 100 |
| Aldosterone inhibitors* (%) | 92.8 | 91.4 | 95.8 |
ACE, angiotensive converting enzyme; BNP, brain natriuretic peptide; CRT, cardiac resynchronization therapy; NYHA, New York Heart Association; QoL, quality of life; 6MWT, 6‐min walking distance.
*
Non‐statistically significant differences between the two subgroups at baseline for all markers (P > 0.05).